Clinical Trials Browser

Recruiting × INDUSTRY × Neoplasm, Residual × Clear all

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

104 enrolled

Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05232916 2026-03-19

FLAMINGO-01

Phase 3 Recruiting

750 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

250 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07211178 2026-03-04

GEMINI Breast

Recruiting

900 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT01499394 2026-01-21

Caris Biorepository Research Protocol

Recruiting

100,000 enrolled

Tumor-Agnostic

Neoplasms, Neoplasm, Residual

NCT06963307 2025-05-09

LumenDx

Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06230185 2025-01-07

B-STRONGER-I

Recruiting

422 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04466059 2024-12-17

BELUGA

Recruiting

25,000 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasm, Residual, Hematologic Neoplasms

Clinical Trials

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

FLAMINGO-01

ALPHA3

GEMINI Breast

Caris Biorepository Research Protocol

LumenDx

B-STRONGER-I

BELUGA